VIDEO: Study examines FLT-3 inhibitors in leukemia treatment
Click Here to Manage Email Alerts
In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined the use of FLT-3 inhibitors in leukemia patients with an FLT-3 mutation.
Lai, an assistant professor of clinical medicine at the University of Pennsylvania, highlighted the study, which looked at patients receiving treatment with the FLT-3 inhibitors midostaurin (Rydapt, Novartis) and quizartinib (Vanflyta, Daiichi-Sankyo), and comparing them to Gilterinib (Xospata, Astellas).
“At this time, only midostaurin and quizartinib are approved in the newly diagnosed setting. But I think more to come on gilteritinib, because this drug is very well tolerated and does have a different side effect profile compared to the other two,” Lai said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts